High-yield and Functional IgY Anti-S1 SARS-CoV-2 Delta Variant from Chicken Immunized with In-house Recombinant Protein
Abstract
BACKGROUND: During COVID-19 pandemic, effective preventive and therapeutic strategies was urgently necessary, especially with the emerging Delta variants. Previous existing interventions have some limitations, and passive immunization using immunoglobulin Y (IgY) is considered viable. However, the potential of IgY antibodies remains underexplored locally. Therefore, a feasible study was conducted to produce IgY against the SARS-CoV-2 Delta variant from chickens raised on a farm, instead of a laboratory environment, by using in-house recombinant protein, to offer a promising low-cost alternative for passive immunization.
METHODS: In-house HEK293 cell line was produced by secreting recombinant S1 subunit protein of SARS-CoV-2 Delta variant. The protein was confirmed by western blot and used as an immunogen in two chickens. IgY was extracted from egg yolks. Titers and neutralization activity of IgY against SARS-CoV-2 Delta variant were confirmed by enzyme-linked immunosorbent assay (ELISA) and surrogate virus neutralization test (sVNT). The functionality of IgY was then tested on lysates from COVID-19 patients' nasopharyngeal swabs with dot blot method.
RESULTS: The high anti-S1 IgY titers and neutralization activity was confirmed following immunization with 1 mg immunogen at 2–3-week intervals. IgY titers varied between chickens and time points. The mean titers showed significant increase after the fifth immunization (1.21, 1.72 and 1.48; with p<0.05 for all). Neutralization activity appeared after the second immunization and was significant after the third immunization (31.9%, 34.95%, 26.9%, 47.6%, 54.95% and 57.3%; with p<0.05 for all). The results of this study showed that the extracted IgY reacted to COVID-19 patients' nasopharyngeal swabs lysates.
CONCLUSION: A high-yield and functional IgY anti-S1 SARS-CoV-2 Delta variant can be produced from chicken immunized with an in-house recombinant protein. This can be an alternative for affordable and effective IgY production during public health emergencies.
KEYWORDS: IgY, SARS-CoV-2, S1 subunit protein, egg yolk, chicken
References
World Health Organization [Internet]. Weekly epidemiological update on COVID-19 [updated 2022 Mar 22; cited 2024 Jan 10]. Available from: www.who.int.
Lestari K, Babikian H, Kulsum ID, Ferdian F, Ismail E, Sumalim Y, et al. The combination of Gardenia jasminoides, Boswellia serrata, Commiphora myrrha, Foeniculum vulgarae, and Daucus carota essential oil blend improved the inflammatory and clinical status in respiratory tract infection of COVID-19 patients: A multicentre, randomized, open-label, controlled Trial. Indones Biomed J. 2024; 16(3): 237-47, CrossRef.
Chukkayapalli SG, Suravaram S, Reddy BK, Siddiqui IA. Genotype AA of ACE2 G8790A (rs2285666) has protective potential against COVID-19 disease severity. Mol Cell Biomed Sci. 2023; 7(3): 155-61, CrossRef.
Centers for Disease Control and Prevention [Internet]. Symptoms of COVID-19 [cited 2024 Jan 10]. Available from: www.cdc.gov.
Tandirogang N, Fitriany E, Mardania N, Jannah M, Dilan BFN, Ratri SR, et al. Neutralizing antibody response by inactivated SARS-CoV-2 vaccine on healthcare workers. Mol Cell Biomed Sci. 2023; 7(1): 18-27, CrossRef.
Shanmugaraj B, Malla A, Phoolcharoen W. Emergence of novel coronavirus 2019-nCoV: Need for rapid vaccine and biologics development. Pathogens. 2019; 9(2): 148, CrossRef.
Hoffmann M, Kleine-Weber H, Pohlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020; 78(4): 779-84, CrossRef.
Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci. 2020; 117(21): 11727-34, CrossRef.
Wilks SH, Mühlemann B, Shen X, Türeli S, LeGresley EB, Netzl A, et al. Mapping SARS-CoV-2 antigenic relationships and serological responses. Science. 2023; 382(6666): eadj0070, CrossRef.
Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ. The receptor-binding of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020; 5(48): eabc8413, CrossRef.
Yuan M, Liu H, Wu NC, Wilson IA. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochem Biophys Res Commun. 2021; 538: 192-203, CrossRef.
Lu Y, Wang Y, Zhang Z, Huang J, Yao M, Huang G, et al. Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping. J Immunol Res. 2020; 2020: 9465398, CrossRef.
Callaway E. Delta coronavirus variant: Scientists brace for impact. Nature. 2021; 595(7865): 17-8, CrossRef.
GSAID [Internet]. Tracking of hCoV-19 Variants [cited 2025 May 13]. Available from: gisaid.org.
Latarissa IR, Barliana MI, Meiliana A, Sormin IP, Sugiono E, Kartasasmita CB, et al. Efficacy of quinine sulfate in patients with mild-to-moderate COVID-19: A randomized controlled trial. Indones Biomed J. 2023; 15(6): 366-74, CrossRef.
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020; 14(1): 69-71, CrossRef.
Wang M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-71, CrossRef.
Sparrow E, Friede M, Sheikh M, Torvaldsen S. Therapeutic antibodies for infectious diseases. Bull World Heal Organ. 2017; 95(3): 235-7, CrossRef.
Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS. 2015; 10(3): 129-34, CrossRef.
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID 19 with convalescent plasma. JAMA. 2020; 323(16):1582-9, CrossRef.
Pereira EPV, van Tilburg MF, Florean EOPT, Guedes MIF. Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review. Int Immunopharmacol. 2019; 73: 293-303, CrossRef.
Schade R, Calzado EG, Sarmiento R, Chacana PA, Porankiewicz-Asplund J, Terzolo HR. Chicken egg yolk antibodies (IgY-technology): A review of progress in production and use in research and human and veterinary medicine. Altern Lab Anim. 2005; 33(2): 129-54, CrossRef.
Rahman S, Van Nguyen S, Icatlo FC Jr, Umeda K, Kodama Y. Oral passive IgY-based immunotherapeutics: A novel solution for prevention and treatment of alimentary tract diseases. Hum Vaccin Immunother. 2013; 9(5): 1039-48, CrossRef.
Krief A, Letesson J, Billen D. Comparison between 'IgY technology' from chickens and 'IgG technology' from mice for production of tailor-made antibodies. Tetrahedron Lett. 2020; 43(10): 1843-6, CrossRef.
Pérez de la Lastra JM, Baca-González V, Asensio-Calavia P, González-Acosta S, Morales-delaNuez A. Can immunization of hens provide oral-based therapeutics against COVID-19? Vaccines. 2020; 8(3): 486, CrossRef.
Lee L, Samardzic K, Wallach M, Frumkin LR, Mochly-Rosen D. Immunoglobulin Y for potential diagnostic and therapeutic applications in infectious diseases. Front Immunol. 2021; 12: 696003, CrossRef.
Vega CG, Bok M, Vlasova AN, Chattha KS, Fernández FM, Wigdorovitz A, et al. IgY antibodies protect against human rotavirus induced diarrhea in the neonatal gnotobiotic piglet disease model. PLoS One. 2012; 7(8): e42788, CrossRef.
Torché A-M, Dimna M Le, Corre P Le, Mesplède A, Gal S Le, Cariolet R, et al. Immune responses after local administration of IgY loaded-PLGA microspheres in gut-associated lymphoid tissue in pigs. Vet Immunol Immunopathol. 2006; 109(3-4): 209-17, CrossRef.
Abbas AT, El-Kafrawy SA, Sohrab SS, Azhar EIA. IgY antibodies for the immunoprophylaxis and therapy of respiratory infections. Hum Vaccin Immunother. 2019; 15(1): 264-75, CrossRef.
Bao L, Zhang C, Lyu J, Yi P, Shen X, Tang B, et al. Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker. J Appl Microbiol. 2022; 132(3): 2421-30, CrossRef.
Rhein C, Scholz T, Henss L, Wiedemann R, Scwarz T, Rodionov R, et al. Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma. J Virol Methods. 2021; 288: 114031, CrossRef.
Armimi A, Syuaib AF, Vanya K, Tan MI, Natalia D, Chen DV, et al. SARS-CoV-2 neutralization assay system using pseudo-lentivirus. Indones Biomed J. 2023; 15(2): 179-84, CrossRef.
Aston EJ, Wallach MG, Narayanan A, Egaña-Labrin S, Gallardo RA. Hyperimmunized chickens produce neutralizing antibodies against SARS-CoV-2. Viruses. 2022; 14(7):1510, CrossRef.
Ravlo E, Evensen L, Sanson G, Hildonen S, Ianevski A, Skjervold PO, et al. Antiviral immunoglobulins of chicken egg yolk for potential prevention of SARS-CoV-2 infection. Viruses. 2022; 14(10): 2121, CrossRef.
Schade R, Bürger W, Schöneberg T, Schniering A, Schwarzkopf C, Hlinak A, et al. Avian egg yolk antibodies. The egg laying capacity of hens following immunisation with antigens of different kind and origin and the efficiency of egg yolk antibodies in comparison to mammalian antibodies. ALTEX. 1994; 11(2): 75-84, PMID.
Institute for Health Metrics and Evaluation [Internet]. COVID-19 Results Briefing [updated 2022 Dec 15; cited 2024 Jan 10]. Available from: www.healthdata.org.
Wiyono A, Adjid RMA, Suhardono, Widiastuti R, Noor SM, Nuradji H, et al. Petunjuk teknis aspek kesehatan hewan ternak ayam mendukung program perbibitan ternak balitbangtan dan program bedah kemiskinan rakyat sejahtera ("bekerja") di Balitbangtan. Bogor: Balai Besar Penelitian Veteriner; 2019, article.
DOI: https://doi.org/10.18585/inabj.v17i4.3693
Copyright (c) 2025 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
